MedPage Today11h
FDA Expands Guselkumab Approval to Crohn's Disease
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
PharmExec12h
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
Healio15h
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Center for Biosimilars19h
The Top 5 Biosimilar Articles for the Week of March 17
Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...
The Pharma Letter19h
FDA nod for Tremfya as J&J builds on Stelara transition
US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...